In view of the ongoing Covid-19 pandemic, Digital Life Line plans to commercialise the new saliva-based ART kits, subject to Digital Life Line’s ability to obtain approval from the relevant regulatory authority.
DISA has announced that a subsidiary of the company, Digital Life Line, has signed a tri-party licensing agreement with the National University of Singapore (NUS) and Singapore Health Services (SingHealth) on Dec 8 for the use of their new saliva-based Covid-19 antigen rapid test (ART) technology.
This technology was co-developed by SingHealth Duke-NUS Academic Medical Centre and the NUS. Dubbed the Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), the technology produces results in minutes, without the need for additional equipment or specially-trained personnel.
